CAPRELSA is a kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer, particularly in cases with unresectable locally advanced or metastatic disease.

Therapeutic Use and Efficacy of CAPRELSA

CAPRELSA (vandetanib) is indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. It is specifically used in patients whose disease has not responded to conventional therapies or who are not candidates for surgical intervention. The therapeutic action of CAPRELSA is attributed to its ability to inhibit multiple receptor tyrosine kinases involved in cancer cell proliferation, survival, and angiogenesis. Although effective for patients with progressing or symptomatic MTC, the drug should be used cautiously in asymptomatic or indolent cases due to its associated risks.